Economic Evaluation Of Cetuximab for Metastatic Colorectal Cancer (mCRC): A Protocol For Evidence Synthesis

Authors

Septiara Putri, Health Policy and Administration Department, Faculty of Public Health Universitas IndonesiaFollow
Ery Setiawan, Center for Health Economics and Policy Studies (CHEPS) Universitas Indonesia, IndonesiaFollow
Siti Rizny F. Saldi, The Center for Clinical Epidemiology and Evidence-Based Medicine, Faculty of Medicine Universitas Indonesia - dr. Cipto Mangunkusumo Hospital, Jakarta, IndonesiaFollow
Levina Chandra, Department of Community Medicine, Faculty of Medicine, Universitas IndonesiaFollow
Amila Megraini, Department Health Administration and Policy, Faculty of Public Health, Universitas Indonesia, Depok, IndonesiaFollow
Vetty Yulianty P, Health Policy and Administration Department, Faculty of Public Health Universitas IndonesiaFollow

Abstract

Colorectal cancer is fairly common compared to other cancers. The incidence and mortality rates are predicted to increase globally. In some cases, cancer can be potentially spread to another organ or metastatic. One of recent available targeted therapies for metastatic colorectal cancer (mCRC) patient is Cetuximab (Erbitux ®), combined with chemotherapy. Despite clinical effectiveness, there is the importance of the evidence related cost-effectiveness of therapy. This study aims to summary, synthesize, and systematically review the economic evaluation studies of Cetuximab for metastatic colorectal cancer (mCRC). Model based economic evaluation of Cetuximab for metastatic colorectal cancer will be searched and included in the review based on specific eligibility criteria. Several electronic databases that will be used: Medline, Embase, Cochrane, National Institute of Health Research (NIHR) Center for Reviews and Dissemination. Full economic evaluation evidence will be summarized and critically appraised using Drummond as well as (Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist. In terms of analysis, we will qualitatively appraise and present the studies that meet our inclusion and exclusion criteria. We are expected to summarize the quality and capture the valuable insights related to health economic evaluation studies of Cetuximab for mCRC patient.

Bahasa Abstract

Kanker kolorektal cukup umum terjadi dibandingkan kanker lainnya, angka kejadian dan angka kematian diprediksi meningkat secara global. Dalam beberapa kasus, kanker berpotensi menyebar ke organ lain atau disebut metastasis. Salah satu terapi yang ditargetkan baru-baru ini untuk pasien kanker kolorektal metastatik (mCRC) adalah Cetuximab (Erbitux®), yang dikombinasikan dengan kemoterapi. Meskipun terdapat bukti klinis, penting untuk mempertimbangkan bukti terkait efektivitas biaya dari terapi tersebut. Penelitian ini bertujuan untuk merangkum, mensintesis, dan meninjau secara sistematis studi evaluasi ekonomi Cetuximab untuk kanker kolorektal metastatik (mCRC). Evaluasi ekonomi berbasis model untuk menilai Cetuximab pada kanker kolorektal metastatik akan ditelusuri sesuai dengan kriteria yang ditetapkan. Beberapa database elektronik yang akan digunakan: Medline, Embase, Cochrane, Pusat Penelitian Kesehatan Nasional (NIHR) untuk Tinjauan dan Diseminasi. Bukti evaluasi ekonomi lengkap akan dirangkum dan dinilai secara kritis dengan menggunakan daftar pertanyaan Drummond dan juga Consolidated Health Economic Evaluation Reporting Standards (CHEERS). Dalam hal analisis, kami akan menilai dan menyajikan secara kualitatif studi yang memenuhi kriteria inklusi dan eksklusi. Kami berekspektasi untuk menyimpulkan kualitas dan menangkap informasi yang berkaitan dengan studi evaluasi ekonomi pada Cetuximab untuk pasien mCRC.

Recommended Citation

Putri, Septiara; Setiawan, Ery; Saldi, Siti Rizny F.; Chandra, Levina; Megraini, Amila; and P, Vetty Yulianty (2018) "Economic Evaluation Of Cetuximab for Metastatic Colorectal Cancer (mCRC): A Protocol For Evidence Synthesis," Jurnal Ekonomi Kesehatan Indonesia: Vol. 3: No. 1, Article 1.
DOI: 10.7454/eki.v3i1.2304
Available at: https://scholarhub.ui.ac.id/eki/vol3/iss1/1